Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
1998-10-16
2001-04-10
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S002600, C514S008100, C514S557000, C514S560000, C426S061000, C424S115000, C424S116000, C424S123000
Reexamination Certificate
active
06214875
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a group of compounds, i.e., specific branched-chain fatty acids, with significant anticancer activities, and methods of treating cancer. The invention also relates to a process of producing fermentation products containing said specific branched-chain fatty acids, using specific bacteria strains, preferably in industrial facilities.
2. Description of the Background
Carcinoma is one of the most serious diseases threatening human's health and life. So far the predominant treatments to cancer patients are radiotherapy and chemotherapy. Both have certain toxicity or side effects on humans while suppressing cancer cell growth or killing cancer cells. Therefore extensive investigations have been carried out in order to find an effective anti-carcinogen with minimum side effects and toxicity.
In 1987, when the inventor cultured K562 leukemia cell lines in the laboratory, cells in a culture flask were found to have completely disappeared 48 hours after being contaminated by a kind of rod bacteria. Those rod bacteria were then intentionally harvested and purified, and incubated in soybean media with appropriate inorganic salts. It was found in later animal studies that the fermentation solution effectively inhibited tumor growth with no toxicity or side effects. In the decade since then, thousands of cancer patients, including advanced stage cancer patients, have been treated with the oral liquid developed from this fermentation solution. These include leukemia, tongue cancer, colorectal cancer, breast cancer, prostate cancer, lung cancer, gastric cancer, hepatocarcinoma, melanocarcinoma, renal cancer, esophagus cancer and pancreas cancer patients. Most of them have responded to the oral liquid, such as by symptom improvement, tumor shrinkage or even complete disappearance. Many of these patients are still alive today. The cases included patients in China, Japan, Korea, the United States, and many other countries.
In order to discover the active components in the fermentation solution that play a key role in killing cancer cells, persistent investigations have been carried out for the last ten years. In this period many books and papers were published worldwide trying to explain the anticancer activity of this fermentation solution. Most of these reports suggested that some soybean isoflavones (e.g. genistein, daidzein and saponin) from the soybean media contributed to the anticancer activities of this fermentation solution. On the other hand, some clinical trials indicated that the anticancer activities of soybean isoflavones were not great enough to explain the anticancer effects of the fermentation solution. The inventor has isolated many compounds from the fermentation solution and revealed that the anticancer activities of the solution were largely contributed by 13-methyltetradecanoic acid and 12-methyltetradecanoic acid. Further investigations discovered that other members of the family of branched-chain fatty acids also had significant tumor-inhibition effects. So far there are no other reports in the literature regarding the anticancer activity of specific branched-chain fatty acids.
SUMMARY OF THE INVENTION
The present invention relates to a group of compounds, i.e., specific branched-chain fatty acids, with significant anticancer activities, and methods of treating cancer using these compounds. Comprehensive biochemical and morphological tests have demonstrated that these activities are associated with induction of programmed cancer cell death (apoptosis). Very importantly, the specific branched-chain fatty acids do not kill normal cells. In animal studies, intraperitoneal injection of 13-methyltetradecanoic acid daily up to 800 mg/kg to mice did not reach the LD
50
level (50% lethal dose).
The specific branched-chain fatty acids can be, but are not limited to, those obtained by synthesis, or by isolation from said fermentation products. Particularly, the present invention relates to the fermentation products containing these specific branched-chain fatty acids, which have the capability of inhibiting the growth of cancer cells without any toxic or side effects. The present invention also relates to a process of producing fermentation products containing the specific branched-chain fatty acids, using specific bacteria strains, preferably in industrial facilities.
REFERENCES:
patent: 4877739 (1989-10-01), Yang
patent: 4985466 (1991-01-01), Deguchi
patent: 2020633 (1997-08-01), None
Chemical Abstracts 118:139830, “Higher Fatty Acids as Anticancer Agents and Anticancer Agent Enhancers”, Aug. 1995.*
Hansen, et al., “The Branched-chain Fatty Acids of Mutton Fat. The Isolation of (+)-12-methyltetradecanoic Acid and of 13-methyltetradecanoic Acid,”Biochem. J., vol. 53, pp. 374-378 (1953).
Kaneda, T., “Fatty Acids of the Genus Bacillus: an Example of Branched-Chain Preference,”Bacteriological Reviews, vol. 41, No. 2, pp. 391-418, (1977).
Hansen, R.P., Shorland, F.B. and Cooke, N.J. The Branched-Chain Fatty Acids of Mutton Fat, 2. The Isolation of (+)-12-Methyltetradecanoic Acid and of 13-Methyltetradecanoic Acid. Biochem. J. 53:374(1953).
Hansen R.P., Shorland, F.B. and Cooke, N.J. The Branched-Chain Fatty Acids of Butterfat, 4. The Isolation of (+)-12-Methyltetradecanoic Acid and of 13-Methyltetradecanoic Acid. Biochem. J. 57:297 (1954).
Klein, R.A., Halliday, D. and Pittet, P.G. The Use of 13-Methyltetradecanoic Acid as an Indicator of Adipose Tissue Turnover. Lipids 15:572 (1980).
Pittet, P.G. Bessart, T., Jequier, E., Philippossian, G. and Liardon, R. Adipose Tissue Labelling in Man, Using a Structurally-Labelled Fatty Acid as a Tracer. Intern. J.Vit. Nutr. Res. 53:115(1982).
Faung, S.T., Chiu, L. and Wang C.T., Platelet Lysis and Functional Perturbation by 13-Methyl Myristate, the Major Fatty Acid in Flavobacterium Ranacida. Thromb. Res. 81:91 (1996).
Wells, J.M. Butterfield, J.E. and Revear, L.G., Identification of Bacteria Associated with Postharvest Diseases of Fruits and Vegetables by Cellular Fatty Acid Composition: An Expert System for Personal Computers. Phytophatology 83:445 (1993).
Dee, S.B., Karr, D.E. Hollis, D. and Woss, C.W. Cellular Fatty Acids of Capnocytophaga Species. J. Clin. Microbiol. 16:779 (1982).
Heerdt, B.G. Houston,M.A. and Augenlicht, L.H. Potentiation by Specific Short-Chain Fatty Acids of Differentiation and Apoptosis in Human Carcinoma Cell Lines. Cancer Res. 54:3288 (1994).
Krass Frederick
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Anticancer effects of specific branched-chain fatty acids... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticancer effects of specific branched-chain fatty acids..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticancer effects of specific branched-chain fatty acids... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2459920